Thermo Fisher Scientific Inc. (NYSE: TMO) today published the offer document (the "Offer Document") for its voluntary tenderoffer (the "TenderOffer") for all of the ordinary shares of QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) at an offer price of €39 per share in cash, following approval of the publication by the German Federal Financial Supervisory Authority.
The period for acceptance of the TenderOffer commenced on May 18, 2020, and is scheduled to end at midnight Frankfurt am Main Local Time or 6:00 PM New York Local Time on July 27, 2020. The TenderOffer is subject to certain customary closing conditions, including, among others, the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at QIAGEN's general meeting of shareholders (the "General Meeting"), and a minimum acceptance threshold of at least 75% of QIAGEN's issued and outstanding ordinary share capital as of the end of the acceptance period. The conditions to the TenderOffer are set forth in their entirety in section 12 of the Offer Document.
The QIAGEN Managing Board and Supervisory Board have unanimously recommended that QIAGEN shareholders accept the TenderOffer by tendering their shares and vote in favor of each of the transaction resolutions at the General Meeting.
The transaction is expected to close in the first half of 2021 as previously announced.